Discovering, Developing and Transitioning Biomarkers:
Multiple Pathways to Commercialization - An Event for the West Coast
Ran On Wednesday, September 10 | 12pm PST
Engage News & Brews
Free To Attend!
This online Covance Engager is part of an exclusive event series providing leaders in pharma and biotech an opportunity to explore the latest insights and innovations facilitating the advancement of precision medicine.
These popular events have been adapted to a virtual format, so you can forge connections with key company and industry thought leaders and learn about diagnostic advances that have the potential to expedite end-to-end drug development, from the comfort of your own home.
This Covance Engager explored:
Discovering, Developing and Transitioning Biomarkers: Multiple Pathways to Commercialization
As technological improvements reveal more about the genomic drivers underpinning disease, biomarkers are playing an increasingly important role in cancer care decision making. Despite the predictive and prognostic value of these markers well realised, challenges still exist with their clinical implementation, stalling the development of
therapies targeting aberrant disease pathways.
In this deep dive online event, expert speakers addressed key opportunities to refine study and assay design enabling you to carry your biomarker through all the way to commercialization.
Key Topics Included:
- Early validation of biomarkers and incorporation into trials
- Case studies and evidence for biomarker discovery processes which have been validated over time
- Emerging liquid biopsy applications in biomarker and CDx development
- Fast, efficient and effective data interpretation for supporting informed treatment decision making
Following a live Q&A, attendees mingled with key Covance executives and precision oncology peers to converse and learn how others are addressing today’s most pressing industry challenges.
Who should attend?
This was an event for senior executives from drug development organizations looking to refine trial design, increase identification of patient responders and accelerate delivery of the next generation of targeted therapies in areas of high unmet need.
Should you have any questions, please reach out to email@example.com and we will be in touch!